Lisata Therapeutics (LSTA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 10, 2025, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 9, 2025.

Voting matters and shareholder proposals

• Election of Mohammad Azab, M.D., M.B.A. and Steven M. Klosk, J.D. as Class III directors for a three-year term expiring in 2028.

• Approval sought for an amendment to the 2017 Employee Stock Purchase Plan, increasing available shares from 113,333 to 158,333.

• Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation for named executive officers.

• Advisory vote on the frequency of future stockholder advisory votes on executive compensation.

• Provision to transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.